Found 16 Enz. Inhib. hit(s) for PDB: 2IVU TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 4nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
3D Structure (crystal)TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 49nMAssay Description:Inhibition of human RET cytoplasmic domain (658 to 1114 residues) expressed in baculovirus system preincubated for 15 mins followed by substrate addi...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 97nMAssay Description:Inhibition of human recombinant histidine-tagged RET (700-1020) expressed in Sf9 cells by ELISAMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 100nMAssay Description:Inhibition of RET (unknown origin)More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 102nMAssay Description:Inhibition of RET (unknown origin) pre-incubated for 60 mins before substrate addition in presence of 9 uM ATP by microfluidic assayMore data for this Ligand-Target Pair
TargetKinesin-1 heavy chain/Proto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
University Of Manchester
Curated by ChEMBL
University Of Manchester
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 950nMAssay Description:Inhibition of wild type recombinant human RET using peptide as substrate by fluorimetric analysisMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 3.60E+3nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataKd: >1.00E+4nMAssay Description:Binding constant for RET(V804L) kinase domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataKd: 34nMAssay Description:Binding constant for RET kinase domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataKd: 34nMAssay Description:Binding constant for RET kinase domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataKd: 14nMAssay Description:Binding constant for RET(M918T) kinase domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [1-999,M918T](Homo sapiens (Human))
Ambit Biosciences
Curated by PubChem BioAssay
Ambit Biosciences
Curated by PubChem BioAssay
Affinity DataKd: 34nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataKd: >1.00E+4nMAssay Description:Binding constant for RET(V804M) kinase domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataKd: 14nMAssay Description:Binding constant for RET(M918T) kinase domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [1-999,M918T](Homo sapiens (Human))
Ambit Biosciences
Curated by PubChem BioAssay
Ambit Biosciences
Curated by PubChem BioAssay
Affinity DataKd: 14nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
